TOP TEN perturbations for 39215_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39215_at
Selected probe(set): 206801_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39215_at (206801_at) across 6674 perturbations tested by GENEVESTIGATOR:
hepatocyte (ESC) / HepaRG
Relative Expression (log2-ratio):6.3130198Number of Samples:8 / 12
Experimental | hepatocyte (ESC) |
Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
Control | HepaRG |
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code: |
succinate dehydrogenase B depletion study 1 (siRNA) / control siRNA transfected Hep3B cell sample
Relative Expression (log2-ratio):5.6900864Number of Samples:3 / 3
Experimental | succinate dehydrogenase B depletion study 1 (siRNA) |
Hep3B cells stably transfected with short hairpin vectors containing an siRNA directed to the subunit B of the succinate dehydrogenase. | |
Control | control siRNA transfected Hep3B cell sample |
Hep3B cells stably transfected with empty siRNA expression vector (pU6). |
hepatocyte (ESC) / Hep-G2
Relative Expression (log2-ratio):5.680724Number of Samples:8 / 9
Experimental | hepatocyte (ESC) |
Hepatocyte-like cells differentiated from embryonic stem cells (ESC) | |
Control | Hep-G2 |
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code: |
oxLDL study 4 / untreated retina pigment epithelial cell (APRE-19) sample
Relative Expression (log2-ratio):-4.060251Number of Samples:3 / 3
Experimental | oxLDL study 4 |
Retina pigment epithelial cells (APRE-19) cells were exposed to oxidatively modified low density lipoproteins (ox-LDL) for 48 hours. | |
Control | untreated retina pigment epithelial cell (APRE-19) sample |
Retina pigment epithelial cells (APRE-19) cells without any treatment. |
embryonic development study 1 (8wk) / embryonic development study 1 (4wk)
Relative Expression (log2-ratio):-3.6892052Number of Samples:3 / 3
Experimental | embryonic development study 1 (8wk) |
Human embryos at 8th week after fertilization. Embryos were obtained after therapeutic termination of pregnancy with mifepristone. | |
Control | embryonic development study 1 (4wk) |
Human embryos at 4th week after fertilization. Embryos were obtained after therapeutic termination of pregnancy with mifepristone. |
glioma study 16 (LN-229) / normal astrocyte sample
Relative Expression (log2-ratio):-3.5617628Number of Samples:2 / 3
Experimental | glioma study 16 (LN-229) |
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
glioma study 16 (LN-319) / normal astrocyte sample
Relative Expression (log2-ratio):-3.5231743Number of Samples:2 / 3
Experimental | glioma study 16 (LN-319) |
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2. | |
Control | normal astrocyte sample |
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations. |
embryonic development study 1 (9wk) / embryonic development study 1 (4wk)
Relative Expression (log2-ratio):-3.515624Number of Samples:3 / 3
Experimental | embryonic development study 1 (9wk) |
Human embryos at 9th week after fertilization. Embryos were obtained after therapeutic termination of pregnancy with mifepristone. | |
Control | embryonic development study 1 (4wk) |
Human embryos at 4th week after fertilization. Embryos were obtained after therapeutic termination of pregnancy with mifepristone. |
dilated cardiomyopathy study 2 (right ventricle) / normal right ventricle derived myocardial tissue
Relative Expression (log2-ratio):3.5091276Number of Samples:7 / 6
Experimental | dilated cardiomyopathy study 2 (right ventricle) |
Right ventricle derived myocardial tissue samples obtained from patients with end-stage heart failure (dilated cardiomyopathy; NYHA IV). Samples were prepared from hearts explanted during an orthotopic heart transplantation. Patients have no history of cardiac infarction and/or coronary stenosis. | |
Control | normal right ventricle derived myocardial tissue |
Right ventricle derived myocardial tissue samples obtained from non-failing control hearts. Non-failing donor hearts were not transplanted due to technical reasons and were removed from donor for cardiac valve grafting. |
dilated cardiomyopathy study 8 (non-responder; IA/IgG; 6m) / normal right ventricle interventricular septum tissue
Relative Expression (log2-ratio):3.4763498Number of Samples:13 / 8
Experimental | dilated cardiomyopathy study 8 (non-responder; IA/IgG; 6m) |
Right ventricle interventricular septum tissue samples derived from patients with dilated cardiomyopathy (LVEF: 36 ± 8; NYHA: I, II or III), classified as non-responders to treatment. Samples were obtained via endomyocardial biopsy 6 months after immunoadsorption with subsequent immunoglobulin substitution therapy (IA/IgG; 6m). In all patients, one course of IA was performed on five consecutive days. After the final immunoadsorption session, patients received 0.5-g/kg human intravenous immunoglobulins to restore physiological IgG plasma levels. After the 6-months follow up period patients not displaying an increase of ≥ 5% in the absolute LVEF value (5 LVEF units) and ≥ 20% relative to the LVEF at baseline were classified as non-responders. All patients received stable oral medication (e.g. ACE-inhibitors or angiotensin receptor antagonists, beta-blockers, aldosterone antagonists, digitalis, diuretics) and medication was kept stable for the duration of this study with exception of dose adjustments for diuretics. Patients exclusion criteria were: a) acute infectious diseases, b) cancer, c) chronic alcoholism, d) postpartum cardiomyopathy, e) heart failure due to other known origins (e.g. primary valvular disease), f) coronary heart disease (excluded by angiography at baseline before IA/IgG), g) acute myocarditis (excluded by histopathological analysis of EMBs in accordance with the Dallas criteria). Myocardial biopsies were considered to be inflamed if immunohistochemistry revealed focal or diffuse mononuclear infiltrates with more than 14 leucocytes per square millimetre (CD3+ T-lymphocytes and/or CD68+ macrophages), as well as enhanced expression of HLA class II molecules. | |
Control | normal right ventricle interventricular septum tissue |
Right ventricle interventricular septum samples derived from control patients. Control patients had normal left ventricular systolic function, no myocardial inflammation, no virus persistence and significant cardiac diseases were excluded by echocardiographic and angiographic examinations. Samples were obtained via endomyocardial biopsy for clinical reasons due to suspicion on myocarditis. |